Details for Patent: 8,324,242
✉ Email this page to a colleague
Which drugs does patent 8,324,242 protect, and when does it expire?
Patent 8,324,242 protects KALYDECO, ORKAMBI, TRIKAFTA (COPACKAGED), and SYMDEKO (COPACKAGED), and is included in seven NDAs.
This patent has one hundred and eighteen patent family members in twenty-six countries.
Summary for Patent: 8,324,242
| Title: | Modulators of ATP-binding cassette transporters |
| Abstract: | The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. |
| Inventor(s): | Ruah; Sara Hadida (La Jolla, CA), Hazlewood; Anna (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Van Goor; Fredrick (San Diego, CA), Singh; Ashvani (San Diego, CA), Zhou; Jinglan (San Diego, CA), McCartney; Jason (Cardiff-by-the-Sea, CA) |
| Assignee: | Vertex Pharmaceutical Incorporated (Cambridge, MA) |
| Application Number: | 12/351,447 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,324,242
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-004 | May 3, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO | ⤷ Sign Up | ||||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-005 | May 3, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO | ⤷ Sign Up | ||||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING CYSTIC FIBROSIS | ⤷ Sign Up | ||||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE | ⤷ Sign Up | ||||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,324,242
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1773816 | ⤷ Sign Up | C300748 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1773816 | ⤷ Sign Up | CA 2015 00038 | Denmark | ⤷ Sign Up |
| European Patent Office | 1773816 | ⤷ Sign Up | PA2015028 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1773816 | ⤷ Sign Up | C20150028 00162 | Estonia | ⤷ Sign Up |
| European Patent Office | 1773816 | ⤷ Sign Up | 1590036-8 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
